Nabil Ismaili, Director of Medical Oncology and Radiotherapy Department at Mohammed VI University of Sciences and Health , shared a post on LinkedIn:
“Precision medicine goes proactive in metastatic HR+/HER2- breast cancer.
The 2025 algorithm is built on:
1. Baseline biomarkers (ESR1, PIK3CA).
2. Dynamic ctDNA monitoring (SERENA-6).
3. Targeted switches at mutation emergence.
Title: A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence
Authors: Nabil Ismaili
Read The Full Article
Other articles about Breast Cancer on OncoDaily.